What Regis Technologies does

Regis Technologies is a US-based pharmaceutical services and specialty chemistry company founded in 1956 by Dr. Louis Glunz III and headquartered at 8210 Austin Avenue, Morton Grove, Illinois. The company operates a dual-business model: a chromatography products franchise and a Custom API CDMO services franchise, both anchored at a single cGMP-certified, FDA-inspected facility.

The chromatography business manufactures and distributes high-performance packed columns for analytical and preparative separations, including chiral HPLC and SFC columns (WHELK-O® 1, recognized as USP L102; Reflect™ polysaccharide phases; AZYP chiral phases; CrownSil™ crown ether phases), achiral SFC columns (Celeris™ family), reversed-phase HPLC columns (Evoke™ C18), and immobilized artificial membrane (IAM) columns for biomimetic drug-permeability screening. Adjacent specialty and imaging reagents include ultrapure ion pairing reagents, derivatizing reagents, and bioluminescent substrates (Coelenterazine, D-Luciferin, 4-Chloro-1-Naphthol). A free in-house chiral screening service tests customer compounds across 13 stationary phases with results typically returned within 3 business days.

The CDMO division provides contract development and manufacturing services for small-molecule active pharmaceutical ingredients from preclinical through commercial stages, including analytical development, process chemistry, cGMP scale-up, clinical trial material, commercial API, and high-potency API (HPAPI) manufacturing. Customers are primarily pharmaceutical and biotechnology companies, separation scientists, and drug discovery organizations. Go-to-market combines direct enterprise sales with an authorized distributor network covering more than 80 countries, including named US distributors Chrom Tech, Fisher Scientific, Peeke Scientific, and ColumnTek. On July 30, 2025, Regis Technologies was acquired by ESTEVE (Esteve Química), a Spain-headquartered global pharmaceutical company founded in 1929, bringing approximately 70 skilled professionals into ESTEVE's US operations and positioning Regis as the US foothold of a broader CDMO platform.

Name

Regis Technologies

Legal name

Regis Technologies, Inc.

Website

https://registech.com

Company type

Private

Founded year

1956

Operating status

Operating

Headcount range

51–100 employees

Short description

Regis Technologies is a US-based, cGMP-certified pharmaceutical services company operating two businesses: a proprietary chromatography column and reagent product line sold in 80+ countries, and a custom small-molecule API CDMO including HPAPI manufacturing from preclinical to commercial stages. Acquired by Spain's ESTEVE in July 2025.

Ownership category

akta.pro rank

Product category

Chromatography Products and Pharmaceutical CDMO

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Chromatography columns
• Chiral separation products
• Pharmaceutical CDMO services
• API contract manufacturing
• Specialty reagents

Headquarters

HQ city

Morton Grove

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Chromatography Products: Sale of chromatography columns (chiral, achiral, reversed-phase, IAM), specialty reagents (ion pairing, derivatizing, imaging), and chiral screening services. Products sold directly and through distributors.
2. Custom API CDMO Services: Contract development and manufacturing services for active pharmaceutical ingredients from preclinical through commercial stages. Services include analytical development, process chemistry, cGMP manufacturing, quality assurance, and regulatory support.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Regis Technologies manufactures and sells high-performance chromatography columns (chiral HPLC/SFC, achiral SFC, reversed-phase HPLC, IAM) and specialty/imaging reagents, and provides contract development and manufacturing (CDMO) services for small-molecule active pharmaceutical ingredients from preclinical through commercial stages, including high-potency APIs (HPAPIs). The chromatography business supplies separation scientists globally through direct sales and authorized distributors in 80+ countries, while the CDMO division serves pharmaceutical and biotechnology customers from its Morton Grove, IL facility.

Product overview

Regis Technologies operates as a dual-business company offering both chromatography products and CDMO services. The chromatography portfolio consists of specialized columns (chiral, achiral SFC, reversed-phase, IAM) and specialty/imaging reagents, with flagship products including Whelk-O® 1 chiral columns, Reflect™ Polysaccharide phases, and Celeris™ achiral SFC columns. The CDMO division provides contract manufacturing and development services for small-molecule APIs from preclinical through commercial stages, including HPAPI manufacturing. The company was acquired by ESTEVE in July 2025.

Differentiator

Problem solved

Functional benefit

Products and services

• Whelk-O® 1 Chiral Columns Pirkle-type chiral stationary phase columns for separating enantiomers from compound families including amides, epoxides, esters, ureas, carbamates, ethers, aziridines, phosphonates, aldehydes, ketones, carboxylic acids, and alcohols. Recognized as USP L102 and available in R,R and S,S configurations for peak elution order inversion. Used by analytical and preparative separation scientists in pharmaceutical and chemical industries.
• Reflect™ Polysaccharide Chiral Phases High-performance polysaccharide-based chiral columns available in both coated and immobilized versions, including C-Amylose A, I-Cellulose B, and I-Cellulose C phases. Provide excellent peak shape, improved resolution, and high loading capacity for preparative applications. Sold to separation scientists for analytical and preparative chiral separations.
• AZYP Chiral Phases Novel chiral stationary phases featuring beta-cyclodextrin, hydroxylpropyl, HILIC, alkyl derivatized cyclofructan, derivatized maltodextrin, macrocyclic glycopeptide, quinine-based, teicoplanin aglycone, teicoplanin, and vancomycin chemistries bonded to 2.7 μm superficially porous particles. Used by separation scientists for difficult chiral separations.
• CrownSil™ Crown Ether Chiral Phases Crown ether-based chiral columns for separating chiral compounds containing primary amines and amino acids and their derivatives, including amino alcohols and secondary amines. Sold to separation scientists requiring selective amine separations.
• Celeris™ Achiral SFC Columns Family of achiral stationary phases for supercritical fluid chromatography, including Ethyl Pyridine (2EP, 4EP), Arginine, Amino, PEI, Silica, and Diol phases. Deliver high capacity, broad selectivity, excellent peak shapes, and reproducibility over long column lifetimes. Sold to analytical and preparative separation scientists.
• Evoke™ C18 Reversed-Phase Columns High-performance, scalable reversed-phase HPLC columns for resolving complex samples in pharmaceutical, food, environmental, forensics, and clinical applications. Sold to analytical laboratories across multiple industries.
• IAM (Immobilized Artificial Membrane) Chromatography Columns Phosphatidylcholine-based columns that mimic biological cell membrane surfaces for high-throughput prediction of drug membrane permeability, correlating with Caco-2 and intestinal tissue assays. Sold to drug discovery and lead optimization teams for ADME screening.
• Ion Pairing Reagents Ultrapure ion pairing reagents for improving separation of charged analytes in HPLC, available for both anions and cations. Sold to analytical laboratories performing charged-analyte separations.
• Derivatizing Reagents High-purity GC derivatization reagents including acylation, alkylation, silylation, and chiral derivatization reagents for modifying analyte functional groups to enable chromatographic separation and detection. Sold to analytical laboratories.
• Coelenterazine High-purity bioluminescent reagent for reporter gene assays, ELISA, HTS assays, BRET, and chemiluminescent detection of superoxides. Manufactured in FDA-inspected, GMP-certified facility. Sold to life sciences researchers.
• D-Luciferin High-purity bioluminescent substrate for in vivo and in vitro research including reporter gene assays, whole animal imaging, luciferase assays, and ATP assays. Sold to life sciences researchers.
• 4-Chloro-1-Naphthol Biochemical reagent with 99% purity for colorimetric detection of proteins. Sold to life sciences and analytical laboratories.
• Free Chiral Screening Service Complimentary chiral separation screening service that tests customer compounds across 13 chiral stationary phases under HPLC or SFC conditions to identify optimal columns and methods. Results typically returned within 3 business days. Offered to separation scientists evaluating column purchases.
• Custom API CDMO Services Contract development and manufacturing services for small-molecule active pharmaceutical ingredients from preclinical through commercial stages, including analytical development, process chemistry, cGMP manufacturing, clinical trial material, commercial API, regulatory and CMC support. Delivered from an FDA-inspected, cGMP-certified facility to pharmaceutical and biotechnology companies.
• HPAPI Manufacturing High-potency active pharmaceutical ingredient manufacturing capabilities within cGMP facilities for compounds requiring specialized handling and containment. Delivered to pharmaceutical and biotechnology companies as part of Regis's CDMO offerings.

Quantifiable outcome

• Improved throughput by greater than 3X with core-shell technology
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• ESTEVE (Esteve Química)coreStrategic or Co-development Partner · 30 July 2025ESTEVE CDMO acquired Regis Technologies in July 2025, enabling ESTEVE to expand its contract development and manufacturing services for small-molecule APIs into the US market. The acquisition provides ESTEVE with physical US presence and Regis's cGMP manufacturing capabilities and chromatography product portfolio.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• MilliporeSigma (Merck KGaA Life Science): MilliporeSigma is the dominant broad-line chromatography and lab supplies vendor with a comprehensive chiral and reversed-phase column portfolio. Competes with Regis across all chromatography segments but as part of a much larger lab products portfolio.

Direct peers

• Chiral Technologies (Daicel subsidiary): Chiral Technologies, the Daicel subsidiary focused exclusively on chiral chromatography, is the most direct competitor to Regis's chiral stationary phase business. Overlaps heavily with Regis's Whelk-O® 1 and Reflect™ product lines.
• Daicel Corporation (Chiral Technologies): Daicel, through its Chiral Technologies subsidiary, is the global market leader in polysaccharide-based chiral stationary phases (Chiralcel, Chiralpak). Direct competitor to Regis's Reflect™ polysaccharide chiral phases and competes in the same chiral HPLC/SFC column market serving pharma separation scientists.
• Phenomenex: Phenomenex (part of Danaher) is a major manufacturer of HPLC and SFC columns including Lux chiral phases. Competes directly with Regis's chiral and reversed-phase column portfolio across pharma and life sciences end markets.
• Hovione: Hovione is a privately-held CDMO specializing in small-molecule APIs, including HPAPI capabilities and particle engineering. Comparable to Regis in CDMO service scope, customer type, and HPAPI specialization.
• Cambrex: Cambrex is a leading small-molecule API CDMO offering services from preclinical through commercial manufacturing. Most direct comparable to Regis's CDMO business in scale, services, and customer base.
• Siegfried Holding AG: Siegfried is a Swiss-listed CDMO focused on small-molecule APIs from process development through commercial manufacturing. Comparable to Regis's CDMO business in target customers, service scope, and regulatory positioning.
• ES Industries: ES Industries manufactures specialty HPLC columns including chiral phases. Similar size and specialty focus to Regis, competing in the same niche pharma and life sciences chromatography market.
• Advanced Materials Technology: Manufacturer of HALO core-shell particle columns used in HPLC and SFC. Directly comparable to Regis's WHELK-O® 1 Core core-shell columns and competes in the high-throughput chromatography segment for pharma.
• YMC Co., Ltd. YMC is a Japanese manufacturer of HPLC and SFC columns including CHIRAL ART polysaccharide chiral columns. Directly comparable to Regis in chiral and reversed-phase chromatography for pharmaceutical customers globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/RegisTechInc
• LinkedInlinkedin.com/company/regis-technologies

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regis Technologies